About the only reason I can think of for not specifying the percentage royalty might be that its contingent on something like how good the drug turns out to be. In other words its in the range maybe from 10-15% depending on how well it does in the trials or how much revenue it generates. After all the other figures for the upfront and milestone payments were exact.
